Trial reportBritish journal of cancer1999
Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells.
Trial report in British journal of cancer, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 64 citations in OpenAlex.
- A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens.British journal of cancer · 2004Trial
- The Clinicopathological Significance of the Cyclin D1/E1-Cyclin-Dependent Kinase (CDK2/4/6)-Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers.International journal of molecular sciences · 2024Article
- Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives.Cancers · 2021Review
- Human La Protein: An RNA-Binding Protein Involved in Ovarian Cancer Development and Multidrug Resistance.OncoTargets and therapy · 2020Review
- Knockdown of ALPK2 inhibits the development and progression of Ovarian Cancer.Cancer cell international · 2020Article
- The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.The Journal of biological chemistry · 2019Article
- CyclinD1 promotes lymph node metastasis by inducing lymphangiogenesis in human ovarian carcinoma.International journal of clinical and experimental pathology · 2018Article
- CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early GThe Journal of biological chemistry · 2017Article
- Mining TCGA data using Boolean implications.PloS one · 2014Article
- Expression of cyclin d1 and its association with disease characteristics in bladder cancer.Anticancer research · 2013Article
- Article
- Cyclin D as a therapeutic target in cancer.Nature reviews. Cancer · 2011Review
- Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.The Biochemical journal · 2011Review
- Cyclin D1 predicts the prognosis of advanced serous ovarian cancer.Experimental and therapeutic medicine · 2011Article
- Microenvironment and pathogenesis of epithelial ovarian cancer.Hormones & cancer · 2010Review
- Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms.Oncogene · 2009Review
- Impact of differential cyclin D1 expression and localisation in prostate cancer.British journal of cancer · 2007Article
- The cyclin D1b splice variant: an old oncogene learns new tricks.Cell division · 2006Article
- Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways.Oncogene · 2004Article
- Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.The American journal of pathology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of cyclin D1 protein in tumour sections from 81 patients with epithelial ovarian cancer was analysed using immunohistochemistry. The tumours that overexpressed cyclin D1 in more than 10% of neoplastic cells were considered positive. Thus overexpression of cyclin D1 was observed in 72/81 (89%) of the cases examined. Protein was detected in both the nucleus and the cytoplasm in 24/81 (30%) and localized exclusively in the cytoplasm in 48/81 (59%) of the tumours. Cyclin D1 was overexpressed in both borderline and invasive tumours. There was no association between protein overexpression and tumour stage and differentiation. Furthermore, no correlation between cyclin D1 expression and clinical outcome was observed. However, in tumours overexpressing cyclin D1 (n = 72), the proportion displaying exclusively cytoplasmic localization of protein was higher in those with serous compared with non-serous histology (P = 0.004, odds ratio 4.8, 95% confidence interval 1.4-19.1). Western analysis using a monoclonal antibody to cyclin D1 identified a 36 kDa protein in homogenates from seven tumours displaying cytoplasmic only and one tumour demonstrating both nuclear and cytoplasmic immunostaining. Using restriction fragment length polymorphism polymerase chain reaction and PCR-multiplex analysis, amplification of the cyclin D1 gene (CCND1 was detected in 1/29 of the tumours demonstrating overexpression of cyclin D1 protein. We conclude that deregulation of CCND1 expression leading to both cytoplasmic and nuclear protein localization is a frequent event in ovarian cancer and occurs mainly in the absence of gene amplification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.